Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)

Comparison of Effect of Propranolol, Bisoprolol, Pyridosgitmine in Postural Orthostatic Tachycardia Syndrome (POTS) and Prognosis After Medical Treatment

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02171988

Acronym

POTS

Enrollment

150

Registered

2014-06-24

Start date

2014-03-31

Completion date

2016-12-31

Last updated

2018-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postural Orthostatic Tachycardia Syndrome

Keywords

Postural Orthostatic Tachycardia Syndrome, propranolol, bisoprolol, pyridostigmine

Brief summary

The purpose of the study is to investigate effect of medical treatment and prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)

Detailed description

Many patients who complained of dizziness are eventually diagnosed as POTS. However, the investigation of an appropriate medical treatment of POTS has not been enough yet. Also, the prognosis of the disease after treatment is not well known. It is known that propranolol attenuate the tachycardia and improve symptom burden in patients with POTS. However, the effect of other β-Blocker, bisoprolol compared with propranolol is not known well. In addition, acetylcholinesterase inhibition with pyridostigmine was a effective method of acutely decreasing the tachycardia in patients with POTS. However, difference among three medical treatments effect is not known and long-term studies are not done yet. Therefore, in this study investigator investigate effect of medical treatment (propranolol only, bisoprolol only, propranolol+pyridostigmine, bisoprolol+pyridostigmine) and prognosis of Postural Orthostatic Tachycardia Syndrome. Longer-term studies are needed to assess this promising therapy.

Interventions

DRUGBisoprolol+pyridostgmine

Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable

DRUGPropranolol

Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable

DRUGBisoprolol

Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable

DRUGPropranolol+pyridostigmine

Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

15 Years to 85 Years

Healthy volunteers

Inclusion criteria

* aged 15\<= * developed symptoms of orthostatic intolerance accompanied by a HR rise ≥30 min-1 within the first 10 minutes of standing, HR rise ≥ 120 in the absence of orthostatic hypotension (a fall in blood pressure \[BP\] \>20/10 mm Hg).

Exclusion criteria

* poor drug compliance * patients who cannot or do not want to write questionaires. * patients who do not want draw blood

Design outcomes

Primary

Measure	Time frame
The change of the subjective symptom survey result after 3-month medical treatment.	3 month after medical treatment

Secondary

Measure	Time frame
Normalization of orthostatic BP-HR test after 6-month medical treatment.	6 month
The change of the subjective symptom after 6-month medical treatment.	6 month
Change of quality of life score after treatment	6 month
Change of depression score after treatment	6 month

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026